The majority of human malignancies have aberrancies in the Retinoblastoma (Rb) pathway. Loss in Rb function results from the phosphorylation and inactivation of Rb by the cyclin-dependent kinases (cdks), main regulators of cell cycle progression. Thus, modulators of cdks may have a role in the treatment of human malignancies. Flavopiridol, the ®rst cdk modulator tested in clinical trials, demonstrates interesting preclinical features: cell cycle block, induction of apoptosis, promotion of dierentiation, inhibition of angiogenic processes and modulation of transcriptional events. Initial clinical trials with infusional¯avopiridol demonstrated activity in some patients with lymphomas and renal, colon gastric carcinomas. Main side eects were diarrhea and hypotension. Phase 2 trials with infusional¯avopiridol, other schedules and combination with standard chemotherapies are ongoing. The second cdk modulator tested in clinical trials, UCN-01, is a PKC inhibitor that can also modulate cdk activity. Similar to¯avopiridol, UCN-01 blocks cell cycle progression and promotes apoptosis. Moreover, UCN-01 may abrogate checkpoints induced by genotoxic stress due to inhibition of chk1 kinase. The ®rst clinical trial of UCN-01 demonstrated very prolonged half-life (*600 h), due to high binding anity of UCN-01 to the human alpha-1-acid glycoprotein. Main side eects were headaches, vomiting, hypoxemia and hyperglycemia. Clinical activity was observed in some patients with melanoma and lymphoma. Trials of shorter infusions of UCN-01 or in combination with standard chemotherapeutic agents are ongoing. Although several important basic and clinical questions remain unanswered, development of cdk modulators is a reasonable strategy for cancer therapy. Oncogene (2000) 19, 6600 ± 6606.
Keywords: cell cycle;¯avopiridol; UCN-01; cyclindependent kinases; cyclin D1; protein kinases; apoptosis Cell cycle abnormalities and Rb pathway derangement in human malignancies: Rationale for modulation of cdks in the treatment of human malignancies Progression through G1 to S phase upon mitogenic stimulation requires the phosphorylation and inactivation of the Retinoblastoma gene product (Rb), a tumor suppressor gene product important for G1 transition (Hatakeyama and Weinberg, 1995; Weinberg, 1995) . As a result of Rb phosphorylation, the phosphorylated Rb is unable to bind and inactivate the transcription factor E2F1, leading to transactivation of E2F-dependent genes and progression to S phase (Dyson, 1998; Hatakeyama and Weinberg, 1995; Zhang et al., 1999) . Rb is phosphorylated and inactivated by a family of serine/threonine kinases, known as cyclin-dependent kinases (cdks) (Morgan, 1997) . These key regulators of the cell cycle are enzymes that periodically form complexes with proteins known as cyclins, cofactors required for the cdk activity. There are at least nine dierent cdks (cdk1 ± cdk9) and many more cyclins (cyclin A through T) (Grana et al., 1994; MacLachlan et al., 1995; Morgan, 1997; Peng et al., 1998; Rickert et al., 1996; Wei et al., 1998) . Dierent cdks operate during dierent phases of the cell cycle. For example, cdk4 and cdk6, in concert with their respective D-type cyclin partners, are responsible for progression through G1, and cdk2 in combination with cyclin E is responsible for progression from G1 into S phase. Cdk2/cyclin A is required for progression through S phase, and cdk1 (also known as cdc2) combined with cyclin B is necessary for mitosis to occur (Sherr, 1996) . Cyclin/cdk complexes are in turn regulated by a stoichiometric combination with small inhibitory proteins, the cyclin-dependent kinase inhibitors (CKIs). There are two families of CKI's: the INK4  (inhibitor of cdk4) family members, p16  ink4a , p15   ink4b   ,  p18   ink4c   , p19 ink4d speci®cally inhibit cyclin D-associated kinases and the KIP (kinase inhibitor protein) family members, p21 waf1 , p27 Kip1 and p57 kip2 , bind and inhibit the activity cyclin E/cdk2 and cyclin A/cdk2 complexes (Sherr and Roberts, 1999) . For further information regarding cell cycle control, please refer to these excellent reviews (Grana and Reddy, 1995; Morgan, 1997; Pines, 1995) .
Most human neoplasias have abnormalities in some component of the Rb pathway either due to hyperactivation of cdks as a result of ampli®cation/overexpression of positive cofactors, cyclins/cdks, or downregulation of negative factors, endogenous CKIs, or mutation in the Rb gene product. Thus, Rb inactivation promotes deregulated S phase entry in a way that ignores growth factor signals with loss of G1 checkpoints (Sherr, 1996; Weinberg, 1995) . For instance, in primary squamous head and neck carcinomas (HNSCC), p16
ink4A inactivation was detected in 83%, absence of Rb protein expression indicative of pRb inactivation was identi®ed in 9% tumors and cyclin D1 ampli®cation was detected using¯uorescence in situ hybridization (FISH) in 36% of tumors; therefore, 91% of primary HNSCC contained at least one alteration in the p16/cyclin D1/Rb pathway (Okami et al., 1999) .
We can consider several strategies to modulate cdk activity for therapeutic intervention. These strategies may be divided into eorts to directly target the catalytic cdk subunit, or to manipulate cdk activity indirectly by aicting the regulatory pathways that govern cdk activity. The ®rst group or`direct' chemical inhibitors represent the most immediate opportunity to allow rational design of small molecule cdk inhibitors to interact speci®cally with the ATP binding site of cdks (De Azevedo et al., 1997; Meijer and Kim, 1997; Sausville et al., 1999; Senderowicz et al., 2000a; Senderowicz and Sausville, 2000; Zaharevitz et al., 1999) . Examples of this group include¯avopiridol congeners, polysulfates, butyrolactone I, 9-hydroxyellipticine, toyocamycin derivatives, paullones and purine derivatives. The second group is composed of agents that`indirectly' modulate the activity of the cdks by altering the expression and synthesis of the cdk/cyclin subunits or the endogenous cdk inhibitory proteins (CKIs); by modulating the phosphorylation state of the cdks (threonine 160, threonine 14, tyrosine 15) by targeting protein kinases and/or phosphatases responsible for these post-translational modi®cations, such as cdc25, wee1/myt1 and by manipulating the proteolytic machinery that regulates the catabolism of cdk/cyclin complexes or their regulators . In this review we will focus with the ®rst group, particularly with the ®rst two direct cdk modulators tested in human clinical trials,¯avopiridol and UCN-01.
Examples of cdk modulators in the clinical setting

Flavopiridol
Mechanism of action and antiproliferative eects The semisynthetic¯avonoid,¯avopiridol (L86-8275/HMR 1275) is derived from rohitukine, an alkaloid isolated from a plant indigenous to India (Figure 1 ). Initial studies revealed that¯avopiridol could induce cell cycle arrest at either G1 or G2/M, concordant with the ability of¯avopiridol to inhibit both cdk2 and cdk1, respectively (Kaur et al., 1992; . To determine the eects of¯avopiridol on cdks, studies utilizing puri®ed cdk's showed that¯avopiridol inhibits cdks 1, 2, 4 and 6 in a competitive manner with respect to ATP, with a Ki of 41 nM, with somewhat less potent eect on cdk 7 (cdk-activating kinase) (Carlson et al., 1996a,b; Losiewicz et al., 1994; Singh et al., 1999; Worland et al., 1993) . With the information obtained from the crystal structure of cdk2 and deschloro-¯avopiridol it became evident that avopiridol binds to the ATP binding pocket, with the benzopyran occupying the same region as the purine ring of ATP (De Azevedo et al., 1996) , corroborating our prior biochemical studies with the compound (Carlson et al., 1996a,b; Losiewicz et al., 1994; Singh et al., 1999; Worland et al., 1993) . Recently, Chao et al. (2000) demonstrated that avopiridol inhibits P-TEF (Positive transcription elongation factor, also known as cdk9/cyclin T) in vitro with a Ki *3 nM. Interestingly, in contrast with all cdks tested so far,¯avopiridol was not competitive with ATP in this reaction (Chao et al., 2000) .
Besides the direct cdk eects of this compound, avopiridol depletes cyclin D1, an oncogene that is upregulated in many human neoplasias and, when overexpressed harbors bad prognosis (Fredersdorf et al., 1997; Michalides et al., 1995) . When MCF-7 human breast carcinoma cell line was exposed tō avopiridol, cyclin D1 protein levels decreased within 3 h. This eect was followed by decline in cyclin D3 with no alteration in cyclin D2 or cyclin E protein levels, leading to loss in cdk4 activity (Carlson et al., 1999) . Cyclin D1 depletion can be explained by downregulation of cyclin D1 mRNA due to speci®c decline in cyclin D1 promoter activity, as measured by luciferase reporter assay (Carlson et al., 1999) . Thus, the cyclin D1 transcriptional repression observed with avopiridol is consistent with the eects of¯avopiridol on the mRNA expression of cell cycle genes from yeast cells (Gray et al., 1998) and may be a consequence of P-TEF (cdk9) related processes (Chao et al., 2000) . In summary,¯avopiridol could induce cell cycle arrest by at least three dierent mechanisms: ®rst, by the direct inhibition of cdks; second, by preventing necessary threonine 160 phosphorylation of cdks due to inhibition of cdk7/cyclin H (Carlson et al., 1996a; Worland et al., 1993) , and ®nally, by downregulation of cyclin D1 and cyclin D3, important cofactors for cdk4 and cdk6 activation (Figure 2) .
Several reports suggest that¯avopiridol may have antiangiogenic properties: Brusselbach et al. (1998) Figure 1 Chemical structures of¯avopiridol and UCN-01 Figure 2 Mechanism(s) of G1/S arrest induced by¯avopiridol. Asterisk denotes proven targets for¯avopiridol-induced G1 arrest. In the case of cyclins, cyclin D1 and cyclin D3 are the only G1 cyclins aected by this compound exposed HUVEC human endothelial cells to¯avopir-idol with clear evidence of apoptosis, even in cells that were non-cycling. In another report, Kerr et al. (1999) tested¯avopiridol in an in vivo angiogenesis mouse model; again,¯avopiridol was able to decrease blood formation in a Matrigel model of angiogenesis. Furthermore, Melillo et al. (1999) demonstrated that hypoxia-induced Vascular endothelial growth factor (VEGF) in human monocytes is blunted by the presence of low nM¯avopiridol concentrations. This eect occurs at the mRNA and protein levels and is due to decrease in VEGF mRNA stability. Thus, it is conceivable that¯avopiridol's antitumor activity may also be mediated by antiangiogenic eects. The relationship between these antiangiogenic properties and cdk modulation is unknown.
Another interesting property of¯avopiridol is the induction of a dierentiated phenotype in in vitro models. Lee et al. (1999) tested if¯avopiridol and roscovitine, both cdk2 inhibitors, or cdk2 antisense constructs may induce a dierentiated phenotype in NCI-H358 lung carcinoma cell lines. Clear evidence of mucinous dierentiation along with loss in cdk2 activity was observed with all three compounds. However, each treatment had dierent eects on cell cycle regulatory expression despite similar dierentiated phenotype.
Another important feature of¯avopiridol's action is the induction of apoptosis. Studies from several laboratories revealed that hematopoietic cell lines were exquisitely sensitive to¯avopiridol-induced apoptosis (Arguello et al., 1998; Byrd et al., 1998; Konig et al., 1997; Parker et al., 1998; Senderowicz, in press ). Interestingly,¯avopiridol when administered in leukemia/lymphoma xenografts as a bolus intravenous schedule demonstrated notable antitumor activity, rendering animals tumor-free in the HL-60 models while infusional¯avopiridol in similar models only achieved tumor growth delays (Arguello et al., 1998; Senderowicz, in press ). This signi®cant antitumor eect is due to frank apoptosis and was associated with peak avopiridol plasma concentration *5 ± 8 mM (Arguello et al., 1998) . The mechanism(s) by which¯avopiridol induces apoptosis have not yet been clari®ed. Flavopiridol did not modulate topoisomerase I/II activity. Moreover, in these hematopoietic cell lines neither BCL-2/BAX nor p53 appeared to be involved (Achenbach et al., 2000; Parker et al., 1998) , while in other systems, bcl-2 may be downregulated (Kitada et al., 2000; Konig et al., 1997) . Similar p53-independent apoptosis was observed when¯avopiridol was tested against a panel of squamous head and neck cell lines, including a head and neck cell line (HN30), insensitive to several DNA damaging agents including g-XRT and bleomycin (Patel et al., 1998) . Other groups corroborated these ®ndings in other preclinical models (Achenbach et al., 2000; Bible and Kaufmann, 1996; Chien et al., 1999; Guedez et al., 1999; Kitada et al., 2000; Li et al., 2000a,b; Park et al., 1996; Schrump et al., 1998) . Preliminary evidence from our laboratory demonstrated that¯avopiridol-induced apoptosis in leukemia cell lines is associated with early activation of the MAPK protein kinase family (MEK, p38 and JNK) (Lahusen et al., 2000) . This activation may lead to activation of caspases (Lahusen et al., 2000) . A consistent ®nding observed in most in vitro models of¯a vopiridol-induced apoptosis is the obliteration of this phenomenon by caspase inhibitors (Achenbach et al., 2000; Byrd et al., 1998; Lahusen et al., 2000) . Recently, the apoptotic eects of¯avopiridol in a panel of B-CLL cell lines was associated with downregulation on the antiapoptosis proteins XIAP, Mcl-1 and BAG-1 (Kitada et al., 2000) . The mechanism(s) of downregulation and its relevance for¯avopiridol-induced apoptosis are still unknown. Finally, Achenbach et al. (2000) demonstrated that apoptosis-induced by¯avo-piridol is associated with mitochondrial depolarization without cytochrome c release in SW2 small cell carcinoma cells. Despite all the information gathered with respect to the mechanism(s) responsible for apoptosis by¯avopiridol, it is still unclear whether the loss of cdk activity by¯avopiridol is required for induction of apoptosis. Intense eorts to understand the mechanism of¯avopiridol-induced apoptosis are currently carried out by several investigators.
Flavopiridol, in addition to having antiproliferative eects by itself, can synergize the eects of other standard chemotherapeutic agents (Bible and Kaufmann, 1997; Schwartz et al., 1997) . Synergistic eects were demonstrated when¯avopiridol followed treatment of A549 lung carcinoma cells with paclitaxel, cytarabine, topotecan, doxorubicin or etoposide. In contrast, when¯avopiridol is combined with 5-uorouracil,¯avopiridol needs to be present for 24 h previously to be synergistic. Moreover, the synergistic eects seen with cisplatin were not schedule-dependent (Bible and Kaufmann, 1997) . Furthermore, the synergism between¯avopiridol with cisplatin and/or g-irradiation did not occur in bladder carcinoma models; however,¯avopiridol demonstrated even more potent eects on tumor cell lines that overexpress MDR (Chien et al., 1999) . These extensive preclinical data will be of help to design clinical trials to test these combinations/schedules in the clinic.
Clinical experience with flavopiridol
Flavopiridol Phase I clinical trials Two clinical trials of infusional¯avopiridol administered by a 72 h continuous infusion every 2 weeks have recently been completed Senderowicz et al., 1998b; Senderowicz and Sausville, 2000; Thomas et al., 1997) . This initial schedule was based on preclinical studies with¯avopiridol administered in a protracted fashion that demonstrated cytostatic eect in colorectal (colo 205) and prostate (LnCap/DU-145) carcinoma xenograft models (Sedlacek et al., 1996; Senderowicz and Sausville, 2000) . Seventy-six patients were treated in the NCI Phase I trial. Dose limiting toxicity (DLT) was secretory diarrhea with a maximal tolerated dose (MTD) of 50 mg/m 2 /day63. The mechanism(s) by which¯avopiridol provoked this adverse event is the result of chloride secretion, as determined in in vitro epithelial intestinal models (Shenfeld et al., 1997) . In the presence of anti-diarrhea prophylaxis (combination of cholestyramine and loperamide), patients were able to be treated at higher doses, allowing a second MTD, 78 mg/m 2 /day63. DLTs at the higher dose level consisted of reversible hypotension and a signi®cant pro-in¯ammatory syndrome (fever, fatigue, local tumor pain and modulation of acute phase reactants) (Senderowicz et al., 1998b) . In an eort to understand the pro-in¯ammatory syndrome, we determined prospectively the plasma concentration of dierent cytokines before and durinḡ avopiridol infusion. A dose-dependent signi®cant increase in IL-6 was observed (A Senderowicz, manuscript in preparation). How this cdk inhibitor modulates cytokine expression is being explored in our laboratory.
Some patients with Non-Hodgkin's lymphoma, colon, prostate and kidney cancer showed shrinkage of tumor masses that, in some circumstances, lasted for more than 6 months, including one patient with refractory renal cancer who achieved a partial response. Five patients received¯avopiridol for more than 1 year and one patient received¯avopiridol for more than 2 years. This observed`disease stabilization' is concordant with some preclinical models, where tumor stasis was observed. Plasma¯avopiridol concentrations between 300 ± 500 nM ± active biological concentrations that exceed the concentration to inhibit cdk in vitro ± were safely achieved during our trial (Senderowicz et al., 1998b) . Eorts to determine if these concentrations induced cdk inhibition in tissues from patients in this trial are being undertaken.
In a second Phase I trial also exploring the use of a 72 h continuous infusion every 2 weeks, Thomas et al. (1997) found that the DLT is diarrhea, corroborating the NCI experience. Moreover, plasma¯avopiridol concentrations between 300 ± 500 nM were also observed (Thomas et al., 1997) . Interestingly, one patient with refractory metastatic gastric cancer achieved a sustained complete response without any evidence of disease more than 2 years after discontinuation of avopiridol (Thomas et al., 1997) .
Bolus¯avopiridol Phase I clinical trial In September 1998, we commenced at the Clinical Center, NIH, the ®rst Phase I trial of daily bolus¯avopiridol for 5 consecutive days every 3 weeks based on our striking antitumor eect observed in leukemia/ lymphoma and squamous head and neck carcinoma xenografts treated with¯avopiridol (Arguello et al., 1998; Patel et al., 1998) . As of May 2000, 48 patients were treated in this Phase I trial. The maximal tolerated dose (recommended Phase II dose) is 37.5 mg/m 2 /day for 5 consecutive days . Dose limiting toxicities observed at 53 mg/m 2 /day were nausea/vomiting, neutropenia, fatigue and diarrhea. Other (non-dose limiting) side eects were:`local tumor pain', acute lymphocytopenia and anorexia . To achieve higher plasma concentrations,¯avopiridol was administered for only 3 consecutive days, obtaining a recommended Phase II dose for this schedule of 50 mg/m 2 /day for 3 days. Schedules reducing the number of daily bolus to 1 are being currently (May, 2000) explored .
Other¯avopiridol clinical trials Combination of paclitaxel and¯avopiridol in a Phase I trial demonstrated good tolerability with a dose-limiting pulmonary toxicity (Schwartz et al., 1999) .
Phase II trials of¯avopiridol are being explored using the MTD in the absence of anti-diarrheal prophylaxis (50 mg/m 2 /day) as a 72 h continuous infusion to patients with chronic lymphocytic leukemia, Non-small cell lung cancer, non-Hodgkin's lymphoma, and colon, prostate, gastric, head and neck, and kidney cancer. Phase I trials of¯avopiridol monotherapy using novel schedules and in combination with standard chemotherapeutic agents are also being explored (Bennett et al., 1999; Shapiro et al., 1999; Stadler et al., 2000; Werner et al., 1998; Wright et al., 1998) .
UCN-01
Mechanism of action, antiproliferative eects and abrogation of checkpoint control Staurosporine is a non-speci®c protein kinase inhibitor that shows cell cycle arrest in transformed and non-transformed cells at 1 ± 100 nM (Tamaoki, 1991) . UCN-01 (7-hydroxystaurosporine; see Figure 1 ) is a staurosporine analog that initially showed higher speci®city against several PKC isoenzymes, particularly against the Ca 2+ -dependent protein kinase C (cPKCs) with an IC 50 *30 nM, with lower potency against the novel Ca 2+ -independent PKC's (nPKC's) (IC 50 *500 nM) and no eect against the atypical PKC's (Seynaeve et al., 1994; Takahashi et al., 1987 Takahashi et al., , 1989 . In addition to the eects on PKC, UCN-01 shows prominent antiproliferative eects in several human tumor cell lines (Akinaga et al., 1991 (Akinaga et al., , 1994 Akiyama et al., 1997; Seynaeve et al., 1993; Wang et al., 1995) . In contrast, another highly selective potent PKC inhibitor, GF 109203X shows no antiproliferative eect despite similar capacity to inhibit PKC in vitro (Wang et al., 1995) allowing the conclusion that UCN-01's antiproliferative eect is probably not explained solely by inhibition of PKC.
Another interesting feature of UCN-01 is in the eects on G1 cell cycle progression (Akinaga et al., 1994; Akiyama et al., 1997 Akiyama et al., , 1999 Kawakami et al., 1996; Seynaeve et al., 1993; Shimizu et al., 1996) . Human epidermoid carcinoma A431 cells exposed to UCN-01 displayed clear evidence of G1 arrest. This arrest was accompanied by hypophosphorylation of the tumor suppressor Rb and the accumulation of p21 waf1 and p27 kip1 and appears to be independent of the p53 and Rb status (Akiyama et al., 1997; Shimizu et al., 1996) . In seeking to de®ne the mechanism(s) for cell cycle arrest, UCN-01 displayed moderately potent inhibition of immunoprecipitated cdc2 and cdk2 (IC 50 : 300 ± 600 nM). However, when intact cells were exposed to UCN-01,`inappropriate activation' of the same kinases occurred (Wang et al., 1995) .
A panel of leukemia T-cell lines (Jurkat, Molt-3, Molt-4 and Hut-78) exposed to 300 nM UCN-01 demonstrated clear evidence of apoptosis. These apoptotic eects were not dependent on p53 function but were correlated with the activation of cdk1 and cdk2 from intact cells exposed to UCN-01 (Wang et al., 1995) . Other investigators demonstrated that the potent apoptotic eects observed in B-CLL lines was associated with downregulation of the antiapoptotic proteins XIAP, Mcl-1 and BAG-1 (Kitada et al., 2000) . The mechanism(s) of downregulation and its relevance for UCN-01-induced apoptosis is still unknown.
When asynchronously growing CA-46 Burkitt's lymphoma (a cell line with defective p53 function) are exposed to DNA genotoxic stress such as girradiation, cells arrest before mitosis (G2 checkpoint activation). This pause likely promotes DNA repair in order to prevent cells to segregate damaged chromosome (Elledge, 1996) . The G2 arrest observed after DNA-damaging agents is due to inactivation of the rate-limiting step for progression from G2 to mitosis, cdc2/cyclin B also known as cdk1 (Sanchez et al., 1997) . However, when CA-46 cells are irradiated ®rst, followed by UCN-01, the`inappropriate activation of cdc2/cyclin B' induced by UCN-01 (see above, IC 50 *30 nM) promotes progression to inappropriate/early mitosis`G2 checkpoint abrogation'. This abrogation following DNA damage is associated with the onset of apoptosis (Wang et al., 1996) . These eects could be partially explained by the inactivation of Wee 1 kinase that negatively regulates G2/M transition (Yu et al., 1998) . Recently, several groups discovered that UCN-01 targets chk1, a regulatory kinase important for G2 checkpoint control after DNA damage (Busby et al., 2000; Graves et al., 2000; Sarkaria et al., 1999) . This eect on chk1 can explain the`inappropriate activation' of cdc2 upon DNA damage by UCN-01. Thus, UCN-01 directly inhibits cdks, but in cells more potently aects`upstream' kinases that regulates cdc2 activity. Studies from other groups suggest that not only UCN-01 is able to abrogate the G2 checkpoint induced by DNA-damaging agents but also, in some circumstances, UCN-01 is able to abrogate the S phase checkpoint induced by similar stimuli (Bunch and Eastman, 1997; Shao et al., 1997) .
Another interesting feature of UCN-01 is the observed increased cytotoxicity in cells that harbor mutated p53 (Wang et al., 1996) . In fact, UCN-01 treatment of CA-46 and HT-29 (colon carcinoma tumor cells lines that harbor p53 mutation) displayed signi®cant cytotoxicity. Moreover, MCF-7 cell lines harboring no endogenous p53 due to ectopic expression of the human papillomavirus type-16 E6 protein, showed enhanced cytotoxicity with the combination between DNA-damaging agents, such as cisplatin and UCN-01, compared with the isogenic wild type MCF-7 cell line. This synergistic eect of UCN-01 was also observed with mitomycin C, 5-¯uoruracil, BCNU, camptothecin, among others (Akinaga et al., 1993; Bunch and Eastman, 1996; Hsueh et al., 1998; Husain et al., 1997; Pollack et al., 1996; Shao et al., 1997; Tsuchida and Urano, 1997) . Therefore, it is likely that this preclinical information may guide us in the clinical development of UCN-01 as a modulator of standard chemotherapy in the clinic Wilson et al., 2000) .
Clinical experience with UCN-01 Based on the antitumor activity observed in preclinical models and unique biochemical features including G2 checkpoint abrogation after DNA damage and apoptosis/potent antiproliferative eects in p53 defective cell lines, we performed the ®rst Phase I trial of UCN-01 in humans (Senderowicz et al., 1998a; Senderowicz and Sausville, 2000) . Unique clinical features observed in this initial human experience included an unexpected very prolonged half-life (*600 h), 100 times longer than the half-life observed in preclinical models, probably to a very avid binding to the human plasma protein alpha-1-acid glycoprotein (AGP) Sausville et al., 1998) . Dose limiting toxicities were nausea/ vomiting, symptomatic hyperglycemia and pulmonary toxicity. The MTD of UCN-01 using a 72 h continuous infusion schedule was 42.5 mg/m 2 /day . One patient with refractory metastatic melanoma developed a partial response that lasted 8 months. Another patient with refractory anaplastic large cell lymphoma that had failed multiple chemotherapeutic regimens including high-dose chemotherapy has no evidence of disease more than 3 years after the initiation of UCN-01 . At the recommended Phase II dose (42.5 mg/m 2 /day over 72 h), concentrations of UCN-01 in saliva (*111 nM), deemed to be free of AGP, that may cause G 2 checkpoint abrogation can be achieved. In an eort to determine`free UCN-01' by another methodology, plasma ultracentrifugation from patients in our trial was performed, showing similar results . Furthermore, in order to determine if UCN-01 has the capacity to modulate signaling pathways in human tissues, the assessment of protein kinase C activity, as measured by immunoblots that only recognize phosphorylated adducin (a known PKC substrate) was performed in several tissues from patients in this trial. Clear decline in phospho-adducin content in patients at the 42.5 and 53 mg/m 2 /day levels were determined from bone marrow aspirates and tumor cells (A Senderowicz, submitted for publication). Thus, patients that received UCN-01 showed evidence of PKC modulation in vivo despite high AGP binding. Future trials with shorter infusional and/or in combination with DNA damaging agents are being explored.
Summary
The majority of human neoplasms have an aberrant Rb pathway as the result the`cdk hyperactivation', leading to deregulation of the cell cycle control. Thus, novel cdk modulators are being developed. The ®rst cdk modulators to be tested in clinical trials, avopiridol and UCN-01 have clear eects on cell cycle progression, apoptosis and signi®cant in vivo activity in several preclinical models. Moreover, in early clinical trials, both compounds demonstrate activity in patients with several neoplasms; plasma levels obtained in these clinical trials exceeds the concentrations required to modulate cdk-related functions in vitro. The best schedule to be administered, combination with standard chemotherapeutic agents and demonstration of cdk modulation in tumor samples from patients in these trials are important issues that need to be answered in order to ensure the best possible use of these agents. From a scienti®c standpoint, drugs that modulate cdks are very interesting reagents to continue to elucidate the connections cdks have with cell cycle progression, apoptosis and dierentiation.
Abbreviations cdk, cyclin-dependent kinase; DLT, dose-limiting toxicity; MTD, maximally tolerated dose; IP, intraperitoneal; IV, intravenous; PK, pharmacokinetics
